BridgeBio succeeds in late-stage encaleret study
Source: SeekingAlpha
2025-10-29 10:05:22 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 - Slideshow
- BridgeBio Pharma, Inc. (BBIO) Presents at HFSA 2025 - Slideshow
- BridgeBio Pharma Q3 2025 Earnings Preview
- BridgeBio rises after late-stage muscular dystrophy trial success
Read the full article on Seeking Alpha
For further details see:
BridgeBio succeeds in late-stage encaleret study
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
3.91% G/L:
$71.05 Last:
577,236 Volume:
$70.45 Open:
BBIO Latest News
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
